Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
June 10, 2024 08:00 ET
|
Assembly Biosciences, Inc.
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 – – Phase 1b study portion of multiple...
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
March 06, 2024 09:00 ET
|
BIOXYTRAN, INC.
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023 16:05 ET
|
Assembly Biosciences, Inc.
Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024New data for several pipeline programs presented at IHW and EASL 2023Additional development candidate nomination...
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif.,...
Male Condoms Market to Reach $13.97Bn by 2028 at 8% CAGR with Non-Latex Segment Driving Growth During 2022–2028 | The Insight Partners
July 04, 2023 08:21 ET
|
The Insight Partners
Pune, India, July 04, 2023 (GLOBE NEWSWIRE) -- According to Recently Published Report by The Insight Partners, “Male Condoms Market Size Report, Forecast to 2028 - COVID-19 Impact and Global...
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted...
Anti-Viral Therapies Market Growth ($82.92 Billion by 2028) Driven by Branded Drugs Segment during (2022-2028) – Global Report by The Insight Partners
March 09, 2023 08:46 ET
|
The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023 08:00 ET
|
Assembly Biosciences, Inc.
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN...
Global Antiviral Therapy Market Expected to Generate a Revenue of $79.8 Million by 2026, Growing at a CAGR of 6.7% From 2019-2026 COVID-19 Impact - Exclusive Report by Research Dive
September 14, 2021 09:01 ET
|
Research Dive
New York, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global antiviral therapy market is expected to generate a revenue of $79.8 million by 2026,...
HerpaGreens Review - Negative Side Effects or Real Benefits?
April 16, 2021 02:33 ET
|
Marketing By Kevin
Chicago, IL, April 16, 2021 (GLOBE NEWSWIRE) -- Have you recently been diagnosed with herpes? Is that all that’s been echoing in your head lately? If yes, this isn’t surprising to us, considering...